" 

Also, I""d like to apologize if my edit description for re-adding the anxiety disorders was unnecessarily provocative.  To be honest, I was surprised to see all mention of several approved indications for the drug removed from the article over a sourcing issue, when the approval itself could be viewed as representing a secondary source. My thought was that this situation was a little different from one in which weak sources are used to support fringe claims."